Login to Your Account

Co-formulation players with anti-VEGF, PDGF are taking 'shots' in AMD market

By Randy Osborne
Staff Writer

Tuesday, May 20, 2014
Ophthotech Corp.'s potential $1 billion-plus, ex-U.S. deal with Novartis AG for Fovista, the antiplatelet-derived growth factor (PDGF) agent capable of enhancing the efficacy of anti-VEGF therapies in wet age-related macular degeneration (AMD), added juice to a growing $5 billion market – one about to take the next step into co-formulation.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription